A Double-Blind, Randomized, Placebo-Controlled, Parallel Dose Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Ruxolitinib deuterated (Primary)
- Indications Alopecia areata
- Focus Adverse reactions; Therapeutic Use
- Sponsors Concert Pharmaceuticals
- 08 Aug 2017 According to a Concert Pharmaceuticals media release, the company expects to complete the trial in the second half of 2018.
- 17 Jul 2017 Number of arms has changed from 5 to 3,hence number of patients has also changed from100 to 90.
- 11 Jul 2017 Planned number of patients changed from 100 to 90.